Biotech firms Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio, which will develop gene-editing therapies. The new company raised $75m in a funding round led by Cormorant Asset Management and others, with the funds to be used to continue developing a lead therapy for liver disease. The company plans to build a broad pipeline of epigenetic editors that target hepatic and extrahepatic diseases.
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
